🎬 Jetzt live auf OnkowissenTV: Die ersten #ESMO25-Videos sind da! 💡 Studien-Highlights 🎙️ Expert:innenanalysen 📺 On demand & kostenlos für Fachkreise: 🔗 https://t.co/rXJlYp3um3 #Onkologie #Krebsmedizin #ESMO2025 #MedEd @Mbpzp2 @jcasusce @docchristoffer @GoebellJ

A warm invite to all, we wait for you at #APCCC26 ⭐ Full details & submission https://t.co/U46NMslfll @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell

KEYNOTE 905 Out on #ESMO25 #BladderCancer Study Breakdown the first perioperative study in cisplatin-ineligible muscle-invasive bladder cancerto show survival benefit. Enfortumab vedotin plus pembrolizumab improved event-free survival, overall survival, and pathologic complete

Dear Colleagues at #ESMO25 Honored to present our OncoAlert 🚨 @tompowles1 🇬🇧 who Just presented IMvigor011 showing ctDNA🧬 is a useful predictive and prognostic tool post cystectomy in muscle invasive #BladderCancer with a Concomitant publication on the @NEJM , Direct from the

Dear #ESMO25 Big News from #APCCC26 🚨APCCC is opening a Call for Abstracts! 👉 https://t.co/m1lKsEhhwS Here are @Silke_Gillessen & @AOmlin to tell you why the discussions here in Berlin will be so relevant for APCCC in Lugano 🇨🇭 @APCCC_Lugano Creating new opportunities for

@scserendipity1 @AlisonBirtle @amerseburger @VivekSubbiah @DrYukselUrun @DrL_Krieger @DrMLChua @DrChoueiri Link:

This work was led by @scserendipity1 with his fellow authors: #SimonHughes @AlisonBirtle @amerseburger @VivekSubbiah @DrYukselUrun @DrL_Krieger @DrMLChua #AmitBahl and @DrChoueiri We're deeply grateful to the authors for their time and dedication. 🙏

What an incredible ESMO meeting! It was wonderful to experience such amazing science and catch up with so many friends. Together, we are making progress in the fight to improve survival for our patients in oncology.#ESMO25

🔥 NESCIO at #ESMO2025: Neoadjuvant ICI in ccRCC #kidneycancer 🌟 ARM A 6wks of nivolumab (closed), ARM B ipi+nivo or ARM C nivo+relatlimab; ➡️ARM B vs ARM C ⚪️7% vs 14% pathologic responses, ⚪️ 42.8% bs 14.2% Gr≥3 IR-AEs ⚪️ 35.7 % vs 28.6% Gr≥3 surgical AEs surgical. 🧐Not a

DISCUS tested 3 vs 6 cycles of platinum chemotherapy followed by avelumab in 1st line metastatic UC #ESMO25 .QOL was the primary endpoint showing better results with the 3 cycle arms. It also showed similar PFS,OS and RR in the 2 arms with OS at 18 months from the start of chemo

Intravesical Gemcitabine via TAR200 for BCG - unresponsive NMIBC with CIS +/- papillary tumors is FDA approved. It joins a number of other agents with a spectrum of MOAs. With data generated from single arm trials there is not a clear winner.

🚨 #ESMO25 Highlights Dr. Pasquale Rescigno @UniofNewcastle discussed two cutting-edge abstracts shaping the future of #ProstateCancer care. 🔹 PETRANHA Trial: Saruparib + ARPI shows promising PSA responses and manageable safety in metastatic settings, with lower discontinuation

🟠 3068O – CheckMate-274: Adjuvant nivolumab vs placebo in high-risk muscle-invasive urothelial carcinoma – 5-year efficacy & ctDNA update 👨‍⚕️ Presented by Dr. Matthew D. Galsky #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ Phase III CheckMate-274 compared adjuvant nivolumab (NIVO) vs

POTOMAC #ESMO25 (durvalumab/BCG vs BCG in MIBC) shows delayed EFS (HR0.69)-the same as Sasanlimab in the same setting. There was no enrichment in the CIS population (unlike sasalimab). Not all high risk patients need PD(L)1 therapy but it doesn’t look like we know who does .

#ESMO25 Day 1✅ Energizing discussions today on emerging data in early cancer detection, high risk #NMIBC, low-dose immunotherapies & combination therapies in #BreastCancer. Watch our touchONCOLOGY platforms for full @myESMO highlights! https://t.co/S9TW69wUQA @amerseburger

ALBAN, POTOMAC & CREST #ESMO25 (atezolizumab/sasalimab/in MIBC) @Annals_Oncology show a lot variability. It no easy to conclude exactly which NMIBC patients benefit from ICI therapy. There is over treatment and it’s not without toxicity @JoshMeeks

Adjuvant nivo remains positive for DFS HR-0.73 but still not +ve for OS 0.83 in operable UC #ESMO25 . Enrichment occurred the ctDNA +ves (DFS HR=0.3 & OS HR=0.44) as in IMvigor010. The ctDNA negatives were at much lower risk didn’t seem to benefit from IO (HR-DFS 0.99, OS 0.87)

🟠 LBA108 – POTOMAC: Durvalumab + BCG vs BCG alone in BCG-naïve high-risk NMIBC 👩‍⚕️ Presented by Dr. Maria De Santis #ESMO25 @OncoAlert @MedicalwatchHQ ➡️ POTOMAC (Phase III, randomized, open-label, international) evaluated Durvalumab + BCG induction + maintenance (I+M) vs BCG

Looking forward to #esmo2025! What are the highlights in #GUcancers for Axel S. Merseburger, MD @amerseburger? All exciting results and data presented by experts available on October 19th on #high5oncologcyTV - stay tuned!

🔥 HOT OFF THE PRESS: The RAMPP trial published in @EuropeanUrology 🚨 ❓ Do pts. with oligo-met. #prostatecancer also benefit from radical prostatectomy? Common practice says yes, evidence is sparse. 👍 Our trial supports that concept. https://t.co/QmGVn4XCp6 @MartiniKlinik